1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Texas >
  6. Janssen Pharmaceuticals Acquires XBiotech - Novel Antibody Bermekimab

M&A Deal Summary

Janssen Pharmaceuticals Acquires XBiotech - Novel Antibody Bermekimab

On December 7, 2019, Janssen Pharmaceuticals acquired life science company XBiotech - Novel Antibody Bermekimab from XBiotech for 750M USD

Acquisition Highlights
  • This is Janssen Pharmaceuticals’ 4th transaction in the Life Science sector.
  • This is Janssen Pharmaceuticals’ largest (disclosed) transaction.
  • This is Janssen Pharmaceuticals’ 3rd transaction in the United States.
  • This is Janssen Pharmaceuticals’ 1st transaction in Texas.

M&A Deal Summary
Date 2019-12-07
Target XBiotech - Novel Antibody Bermekimab
Sector Life Science
Buyer(s) Janssen Pharmaceuticals
Sellers(s) XBiotech
Deal Type Divestiture
Deal Value 750M USD

Target

XBiotech - Novel Antibody Bermekimab

Austin, Texas, United States
XBiotech, Inc.'s Novel Antibody Bermekimab provides disease-causing inflammation in a wide range of medical conditions.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Janssen Pharmaceuticals

Titusville, New Jersey, United States
Category Company
Founded 1973
Sector Life Science
DESCRIPTION

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health.

DEAL STATS #
Overall 4 of 4
Sector: Life Science M&A 4 of 4
Type: Divestiture M&A Deals 2 of 2
State: Texas M&A 1 of 1
Country: United States M&A 3 of 3
Year: 2019 M&A 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-25 Nizoral

Fort Washington, Pennsylvania, United States

Nizoral is a anti-dandruff shampoo brand sold in North America and Latin America. Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care.

Sell -

Seller(S) 1

SELLER

XBiotech

Austin, Texas, United States
Category Company
Founded 2005
Sector Life Science
Employees90
Revenue 4M USD (2022)
DESCRIPTION

XBiotech is a biopharmaceutical company dedicated to pioneering the discovery, development, and commercialization of therapeutic antibodies. Utilizing natural human immunity as a source of new medicines offers the potential to redefine the standards of care for a wide range of diseases. XBiotech was founded in 2005 and is based in Austin, Texas.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Texas M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal